reference standard is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
=== Pharmacodynamics === Dextromethorphan acts as an NMDA receptor antagonist, σ1 receptor agonist, and serotonin–norepinephrine reuptake inhibitor, among other actions, while bupropion acts as a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator. Bupropion is also a potent inhibitor of CYP2D6, and thereby inhibits the metabolism of dextromethorphan. Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan, a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan itself. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown, although the preceding pharmacological actions are assumed to be involved.
20 September – Scientists who reported the earliest known interstellar object, CNEOS 2014-01-08, and members of The Galileo Project, report the discovery of an additional candidate interstellar meteor, CNEOS 2017-03-09, in a preprint using the same fireball catalog. They find that the implied material strength of the two objects suggests that interstellar meteors "come from a population with material strength characteristically higher than meteors originating from within the solar system". 21 September – Engineers report the development of autonomous 3D-printing drones for construction and repair. 22 September Nanoengineers report the development of biocompatible microalgae hybrid microrobots for active drug-delivery in the lungs (22 Sep.) and the gastrointestinal tract (GT) (28 Sep.). The microrobots are related to medical nanobots and proved effective in tests with mice. A separate team reports the development of 'RoboCap', a robotic drug delivery capsule that enhances drug absorption by tunneling through the mucus layer in the GT (28 Sep.). Around September, news outlets report about deployment, research and development of novel military drone technology in the Russo-Ukrainian War in 2022, including demining drones, self-repurposed commercial/hobby drones (including via a hackathon), reconnaissance microdrones, kamikaze drones, bomb-dropping modified drones, and countermeasures such as electronic ones.
== Effects on cytotoxic edema == Purinergic receptors have been suggested to play a role in the treatment of cytotoxic edema and brain infarctions. It was found that with treatment of the purinergic ligand 2-methylthioladenosine 5' diphosphate (2-MeSADP), which is an agonist and has a high preference for the purinergic receptor type 1 isoform (P2Y1R), significantly contributes to the reduction of an ischemic lesions caused by cytotoxic edema. Further pharmacological evidence has suggested that 2MeSADP protection is controlled by enhanced astrocyte mitochondrial metabolism through increased inositol triphosphate-dependent calcium release. There is evidence suggesting a relationship between the levels of ATP and cytotoxic edema, where low ATP levels are associated with an increased prevalence of cytotoxic edema. It is believed that mitochondria play an essential role in the metabolism of astrocyte energy within the penumbra of ischemic lesions. By enhancing the source of ATP provided by mitochondria, there could be a similar 'protective' effect for brain injuries in general.
12 June – The ONS reports that the UK economy failed to grow during April. The zero percent growth rate is attributed to unusually high rainfall, well above the long-term average, which impacted consumer spending. 13 June Keir Starmer unveils the Labour Party's general election manifesto. He says that wealth creation is the "number one priority" and that Labour will focus on economic growth. The first commercial-scale liquid air energy storage plant begins development in Carrington, Greater Manchester. Its backers say the £300m facility will create more than 700 jobs and have the capacity to power 480,000 homes. 14 June Tesco reports a 5% increase in sales over the past three months, and says that consumer confidence is beginning to return. Manufacturers are recalling several types of prepacked sandwiches, wraps and salads from major supermarkets amid concerns they could be contaminated with E. coli. Nigel Farage says he is "leader of the opposition" after a YouGov poll shows Reform UK ahead of the Conservative Party for the first time. Rishi Sunak responds by saying that Labour would be handed a "blank cheque" if current polling were replicated at the general election. It is confirmed that the Princess of Wales will attend the 2024 Trooping the Colour ceremony, making her first public appearance since her cancer diagnosis. The 2024 Birthday Honours are released, with those recognised including Alan Bates, the postmaster whose campaign brought the Post Office scandal to public attention.
Sources: en.wikipedia.org
It induces excitotoxicity in rodents by overactivating NMDA and metabotropic glutamate receptors, leading to calcium overload and oxidative damage. In contrast, it targets glutamate-gated chloride channels in invertebrates, causing increased chloride permeability without affecting their excitatory glutamate receptors.
== Medical uses == Lorcaserin was used long term for weight loss in those who are obese. The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8,000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks. All participants received lifestyle modification that consisted of a reduced calorie diet and exercise counseling. Compared with placebo, treatment with Belviq for up to one year was associated with average weight loss ranging from 3 percent to 3.7 percent. About 47 percent of patients without type 2 diabetes lost at least 5 percent of their body weight compared with about 23 percent of patients treated with placebo. In people with type 2 diabetes, about 38 percent of patients treated with Belviq and 16 percent treated with placebo lost at least 5 percent of their body weight. Belviq treatment was associated with favorable changes in glycemic control in those with type 2 diabetes. The approved labeling for Belviq recommends that the drug be discontinued in patients who fail to lose 5 percent of their body weight after 12 weeks of treatment, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment. The drug's manufacturer was required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke.
Portal is a series of first-person puzzle-platform video games developed by Valve. Set in the Half-Life universe, the two main games in the series, Portal (2007) and Portal 2 (2011), center on a woman, Chell, who is forced to undergo a series of tests within the Aperture Science Enrichment Center by a malicious artificial intelligence, GLaDOS, that controls the facility. Most of the tests involve using the "Aperture Science Handheld Portal Device" – nicknamed the portal gun – that creates a human-sized, wormhole-like connection between two flat surfaces. The player-character or objects in the game world may move through portals while conserving their momentum. This allows complex "flinging" maneuvers to be used to cross wide gaps or perform other feats to reach the exit for each test chamber. A number of other mechanics, such as lasers, light bridges, high energy pellets, buttons, cubes, tractor funnels and turrets, exist to aid or hinder the player's goal to reach the exit. The Portal games originated through bringing students and their projects from the DigiPen Institute of Technology into Valve and expanding upon the ideas in Valve's Source engine. The concept was introduced by the game Narbacular Drop, which became the basis for the first game. Another DigiPen game, Tag: The Power of Paint, formed the basis of the "Mobility gels" introduced in Portal 2. Both games have received near-universal praise and have sold millions of copies. The first game was released as part of a five-game compilation, The Orange Box.
== History == The safety and effectiveness of dulaglutide were evaluated in six clinical trials in which 3,342 subjects with type 2 diabetes received dulaglutide. Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control). The US Food and Drug Administration (FDA) approved dulaglutide with a Risk Evaluation and Mitigation Strategy (REMS), and granted the approval of Trulicity to Eli Lilly and Company. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with the drug. In 2020, the FDA approved two higher doses of the medication, 3.0 mg and 4.5 mg, based on results of the AWARD-11 trial demonstrating improved glucose lowering and weight benefits.
== History == Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. In late 2019, Cambrex was acquired by an affiliate of the Permira funds. In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening alongside a biopharmaceutical expansion at its Durham, NC facility. Thomas Loewald was appointed CEO of Cambrex in September 2020. In 2022, Cambrex acquired Q1 Scientific, based out of Waterford, Ireland.
Sources: en.wikipedia.org
Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of proteins that in humans is encoded by the HBEGF gene. HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic and chemotactic glycoprotein. An epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function. First identified in the conditioned media of human macrophage-like cells, HB-EGF is an 87-amino acid glycoprotein that displays highly regulated gene expression. Ectodomain shedding results in the soluble mature form of HB-EGF, which influences the mitogenicity and chemotactic factors for smooth muscle cells and fibroblasts. The transmembrane form of HB-EGF is the unique receptor for diphtheria toxin and functions in juxtacrine signaling in cells. Both forms of HB-EGF participate in normal physiological processes and in pathological processes including tumor progression and metastasis, organ hyperplasia, and atherosclerotic disease. HB-EGF can bind two locations on cell surfaces: heparan sulfate proteoglycans and EGF-receptors effecting cell-to-cell interactions.
=== Incubation period === The delay between the consumption of contaminated food and the appearance of the first symptoms of illness is called the incubation period. This ranges from hours to days (and rarely months or even years, such as in the case of listeriosis or bovine spongiform encephalopathy), depending on the agent, and on how much was consumed. If symptoms occur within one to six hours after eating the food, it suggests that it is caused by a bacterial toxin or a chemical rather than live bacteria. The long incubation period of many foodborne illnesses tends to cause those affected to attribute their symptoms to gastroenteritis. During the incubation period, microbes pass through the stomach into the intestine, attach to the cells lining the intestinal walls, and begin to multiply there. Some types of microbes stay in the intestine, some produce a toxin that is absorbed into the bloodstream, and some can directly invade the deeper body tissues. The symptoms produced depend on the type of microbe. In cases of foodborne illness, particularly traveler's diarrhea, symptoms often result from the immune system's response rather than direct pathogen damage. This inflammatory response can lead to post-infectious irritable bowel syndrome (PI-IBS), where 3–20% of affected individuals develop chronic gastrointestinal symptoms even after the pathogen is cleared. This suggests that the body's immune reaction, particularly inflammation, plays a significant role in both acute symptoms and long-term effects of foodborne illness.
During large-scale protests and demonstrations organized by Generation Z against government corruption in Nepal during September 2025, the flag became a key symbol. Protesters displayed the flag with slogans criticizing the luxurious lifestyles of politicians' children on social media. Posts featuring the flag went viral on Nepalese social media, and its adoption quickly spread among protesters. One Nepalese protester interviewed by The Kathmandu Post remarked that the flag's use in Indonesian protests "surely popularised its use in protests in Nepal". As the government of K. P. Sharma Oli was toppled by the protests, protesters hung the flag at the gates of the Singha Durbar palace as it burned.
=== Wound management === Chitosan has the ability to adhere to fibrinogen, which produces increased platelet adhesion, causing clotting of blood and hemostasis. Chitosan may have other properties conducive to wound healing, including antibacterial and antifungal activity, which remain under preliminary research.
Direct TPMS (dTPMS) directly measures tire pressure using hardware sensors. In each wheel, most often on the inside of the valve, there is a battery-driven pressure sensor which transfers pressure information to a central control unit which reports it to the vehicle's onboard computer. Some units also measure and alert temperatures of the tire as well. These systems can identify under-inflation for each individual tire. Although the systems vary in transmitting options, many TPMS products (both OEM and aftermarket) can display realtime, individual tire pressures whether the vehicle is moving or parked. There are many different solutions, but all of them have to face the problems of exposure to hostile environments. The majority are powered by batteries, which limit their useful life. Some sensors utilise a wireless power system similar to that used in RFID tag reading which solves the problem of limited battery life. This also increases the frequency of data transmission up to 40 Hz and reduces the sensor weight, which can be important in motorsport applications. If the sensors are mounted on the outside of the wheel, as are some aftermarket systems, they are subject to mechanical damage, aggressive fluids, and theft. When mounted on the inside of the rim, they are no longer easily accessible for battery change and the RF link must overcome the attenuating effects of the tire, which increases the energy need. A direct TPMS sensor consists of the following main functions requiring only a few external components — e.g.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.